{
  "docId": "019de074-ca9a-70d9-9ba2-1d5f94361fe0",
  "docSlug": "6d754588aa25b32079af055d51113b03",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 38,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "ADA stands for Anti-Drug Antibodies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ca9a-70d9-9ba2-1d5f94361fe0/13",
  "deckHref": "/decks/019de074-ca9a-70d9-9ba2-1d5f94361fe0",
  "deckJsonHref": "/decks/019de074-ca9a-70d9-9ba2-1d5f94361fe0.json",
  "deckAnchorHref": "/decks/019de074-ca9a-70d9-9ba2-1d5f94361fe0#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.72,
        "x": 0.14,
        "y": 0.0075
      },
      "kind": "callout",
      "text": "Additional cohorts could be used to explore higher doses, longer dosing duration, and the potential to dose through the impact of ADAs",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff0c6be4-6f84-46bc-a79e-754235b246e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.43,
        "x": 0.525,
        "y": 0.00188
      },
      "kind": "list",
      "text": "Safety: Adverse events have been mild to moderate in data gathered to date; Toxicology data indicates a large dosing window and potential to continue dose escalation. Manufacturing: Stable, high-concentration liquid formulation. Regulatory: Orphan Disease, Fast Track and Rare Pediatric Disease designations for Homocystinuria",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0bec738-99a7-4fbc-9e91-48b963f92c7e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.045,
        "y": 0.00188
      },
      "kind": "list",
      "text": "Efficacy: Data from Phase 1/2 clinical trial indicated pegtarviliase is capable of lowering homocysteine levels; Results from cohort 3 did not show consistent homocysteine lowering, likely due to the presence of ADAs; ADAs frequently seen with other pegylated enzyme therapies; potential to dose through pharmacological impact",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ddf6d5f2-4835-4b9b-b09a-784a29dbeba4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.458,
        "x": 0.068,
        "y": 0.045
      },
      "kind": "title",
      "text": "Pegtarviliase Program Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af9482b9-d8ed-4dc9-bdce-643dad0f0f58",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "fa01f467-4466-4aea-bcda-09b35851950e",
      "evidence": "Efficacy: Data from Phase 1/2 clinical trial indicated pegtarviliase is capable of lowering homocysteine levels",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 38,
      "from": 3,
      "beatId": "e469074b-5500-4414-8b81-ef0652ee8a7d",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 3-38 present various traction metrics, including clinical trial results and financial summaries",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}